Acquired Demyelination in Children: Evolving Concepts and Treatment Paradigms

Presented by

J. Nicholas Brenton, MD

Director, Pediatric MS & Related Disorders Clinic

Associate Professor of Pediatrics & Neurology

University of Virginia

Wednesday, December 3, 2025

8:00 – 9:00 AM EST

Zoom only: https://uky.zoom.us/j/89948846670

Upon completion of this activity, participants will be able to:

1. Discuss key clinical features and the appropriate evaluation of acquired demyelination in children
2. Review the most common etiologies of acquired demyelination and how to differentiate and stratify risk for relapse/recurrence
3. Outline the current diagnostic criteria, treatment paradigms, and prognostication factors for relapsing disorders in children with acquired demyelination

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

J. Nicholas Brenton, MD, faculty for this educational event, was a consultant for the Institute for Advanced Clinical Trials (I-ACT) for Children on a Novartis-sponsored project within the past 24 months. The financial relationship has ended.

All of the relevant financial relationships listed for this individual have been mitigated.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.